samedan logo
 
 
 
spacer
home > ebr > winter 2001 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

Welcome to the first issue of EBR under the banner of its new owner, Samedan Ltd. Together with Technomark, Samedan is seeking to expand both the breadth and depth of the magazine, whilst maintaining the quality of the content and heightening focus around the key strategic, technological and ethical themes in our industry. With this in mind, in this issue we have aimed to focus on some of the key informatic and proteomic technologies which have received so much attention of late. For those like me, who really wanted to understand the evolution of the technology behind the hype, the interview with Professor Denis Hochstrasser in Geneva gives both an illuminating personal history and a 'beginner's guide' to both. In terms of commercial activities in this area, two of the three meeting reviews (GenomeX and Biomics) give a thorough overview of who is doing what and with whom, as well as what pharmaceutical partners are expecting and beginning to gain.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Global pharma industry gathers at CPhI Worldwide 2021 as surge in partnering expected in 2022

Over 25,000 online and 23,000 in person attendees at the world’s largest pharma trade exhibition. CPhI Worldwide (9-11 November, 2021), which held its first in-person event since 2019, hosted the global pharma community at the Fiera Milano, Milan, welcoming exhibitors and attendees from 146 countries.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement